資源描述：
《曲妥珠單抗在HER-2陽(yáng)性乳腺癌患者新輔助治療中的應(yīng)用研究進(jìn)展.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在應(yīng)用文檔-天天文庫(kù)。
1、中國(guó)腫瘤臨床2014年第41卷第l6期ChinJClinOncol2014．Vo1．41．No．16WWW．cjco．cn1065·綜述·曲妥珠單抗在HER-2陽(yáng)性乳腺癌患者新輔助治療中的應(yīng)用研究進(jìn)展劉君楊艷芳綜述顧林審校摘要曲妥珠單抗是人表皮生長(zhǎng)因子受體一2(humanepidermalgrowthfactorreceptor一2，HER一2)的特異性抑制劑，在HER一2陽(yáng)性乳腺癌患者新輔助治療中的應(yīng)用日益廣泛。大規(guī)模的隨機(jī)、對(duì)照臨床試驗(yàn)證實(shí)，新輔助化療聯(lián)合曲妥珠單抗與單純化療比較能顯著提高病理完全緩解(pathologiccompleterespons
2、e，pCR)率。在曲妥珠單抗聯(lián)合化療的基礎(chǔ)上加用拉帕替尼較單用曲妥珠單抗可大大提高pCR率。蒽環(huán)與非蒽環(huán)類化療藥物均可作為曲妥殊單抗的聯(lián)合用藥，內(nèi)分泌治療也可作為雌激素受體陽(yáng)性患者的聯(lián)合用藥。pCR是曲妥珠單抗新輔助治療后生存獲益的獨(dú)立預(yù)后因素，HER一2轉(zhuǎn)陰而未達(dá)到pCR的患者為不良預(yù)后因素。本文將對(duì)曲妥珠單抗在HER一2陽(yáng)性乳腺癌患者新輔助治療中的研究進(jìn)展進(jìn)行綜述。關(guān)鍵詞曲妥珠單抗新輔助治療人表皮生長(zhǎng)因子受體一2乳腺癌doi：10．3969／j．issn．1000—8179．20132207Advancedresearchonneoadjuvantth
3、erapywithtrastuzumabinHER2-positivebreastcancerJunLIU，YanfangYANG，LinGUC0rrespondenceto：LinGU；E—mail：gulindr@yahoo．cornTheSecondDepartmentofBreastCancer,TianjinMedicalUniversityCancerInstituteandHospital；NationalClinicalResearchCenterforCancer；KeyLaboratoryofBreastCancerPrevention
4、andTherapy,MinistryofEducation；KeyLaboratoryofCancerPreventionandTherapyTianjin，Tianjin300060，ChinaAbstractTrastuzumabisaspecificinhibitoragainsthumanepidermalgrowthfactorreceptor-2(HER-2．Trastuzumabiswidelyusedintheneo—adjuvanttreatmentofHER一2breastcancer．Large—scalerandomizedand
5、controlledclinicaltrialshavedemonstratedthatpatholog!ccompleteresponserates(pCRs)weresignificantlyincreasedwithneo·adjuvanttrastuzumabtherapypluschemotherapythanwithregularchemotherapy．TheuseoftrastuzumabpluschemotherapywithlapatinibsupplementscouldfurtherimprovepCRrates．An—thracy
6、clineandnon-anthracyclinedrugscouldbothbeusedconcurrentlywithtrastuzumab．Endocrinetherapycouldbeusedasanalter-nativeforestrogenrecept0卜positiVepatients．pCRisapowerfulpredictoroflong—termoutcomesinHER-2positivepatientsunderneo—adjuvanttherapywithtrastuzumab．However,patientlossofHER
7、一2expressionwithresidualdiseaseafterneo—adjuvanttherapywithtrasmmmaabisapoorprognosticfactor．Thisstudypaperwillprovideareviewofrelatedresearch．Keywords：trastuzumab，neo—adjuvanttherapy,HER一2，breastcancer曲妥珠單抗是一種特異性針對(duì)人表皮生長(zhǎng)因子受綜述。體一2(humanepidermalgrowthfactorreceptor一2，HER一2)1曲妥珠單抗新輔
8、助治療fl~III期臨床試驗(yàn)胞外區(qū)的人源化單克隆抗體，目前在HER
